Sort
23,748 grants matching “melanoma”
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$654,706Timothy A Marlowe · Faknostics, Llc · R42 · FY2023 · CA
Reducing Skin Cancer Risk in Childhood Cancer Survivors
$654,652Alan C Geller · Harvard School Of Public Health · R01 · FY2014 · CA
Resistance mechanisms to autophagy-modulating therapies
$654,428Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2025 · CA
Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA
$654,111Douglas C Wallace · Children'S Hosp Of Philadelphia · R01 · FY2022 · CA
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$654,072Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2022 · HL
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
$654,058Robert H Vonderheide · University Of Pennsylvania · P01 · FY2019 · CA
YALE SKIN DISEASES RESEARCH CORE CENTER
$654,000Yale University · P30 · FY2001 · AR
YALE SKIN DISEASES RESEARCH CORE CENTER
$654,000Yale University · P30 · FY2003 · AR
Yale Skin Diseases Research Core Center
$654,000Yale University · P30 · FY2005 · AR
YALE SKIN DISEASES RESEARCH CORE CENTER
$654,000Yale University · P30 · FY2002 · AR
Yale Skin Diseases Research Core Center
$654,000Robert E. Tigelaar · Yale University · P30 · FY2006 · AR
SUN SAFETY INTERVENTION FOR POSTAL CARRIERS
$653,636San Diego State University · R01 · FY2002 · CA
Immune dysregulation mechanisms of persistent post-COVID19 olfactory dysfunction
$653,547Lora Bankova · Brigham And Women'S Hospital · R01 · FY2024 · DC
Redox imaging for breast cancer prognosis
$653,379Lin Z Li · University Of Pennsylvania · R01 · FY2016 · CA
Molecular Analysis of Melanoma Metastasis and Blood in Patients Undergoing Sentin
$653,179Dave S B Hoon · Saint John'S Cancer Institute · P01 · FY2013 · CA
Optimizing TCR-CD3 signaling for immunotherapy of cancer
$652,880Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2024 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$652,762Jin Wang · Baylor College Of Medicine · R01 · FY2022 · CA
Sustaining antitumor effector CD8+ T cells for cancer therapy
$652,206Bin Zhang · Northwestern University At Chicago · R01 · FY2025 · CA
Development of Novel Inhibitors of Ganglioside Biosynthesis
$652,045Brett E Crawford · Zacharon Pharmaceuticals, Inc. · R44 · FY2009 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$651,354Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2021 · CA
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
$651,147Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
MS4A7 in tumor resistance to immunotherapy
$651,124Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance
$651,120Madhavi P Kadakia · Wright State University · R01 · FY2024 · CA
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
$651,026Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2021 · CA
Mutagenic chain reaction-facilitated immunotherapy
$651,000Stephen M Hedrick · University Of California, San Diego · R01 · FY2019 · AI